Heliantriol C

Fig. (6) A shows the time dependence of skin tumor formation in the group treated with DMBA/TPA, with or without 0.2 pM each of 232 and heliantriol C (236). The first tumor appeared at week 8 in the group treated with DMBA/TPA. In the group treated with DMBA/TPA and 232 and 236, the first tumor appeared at weeks 10 and 13, respectively. The percentage of tumor-bearing mice treated with DMBA/TPA was 93% at week 20,...

Fig. (6). Inhibitory effect of faradiol (232) and heliantriol C (236) on the promotion of skin papillomas by TPA in DMBA-initiated mice. Starting 1 week after initiation by a single topical application of 50 pgof DMBA, 1 pg of TPA was applied twice weekly. Topical application of 232 (0.2 pmol), 236 (0.2 gmol) and vehicle was performed 30 min before each TPA treatment. Data are expressed as percentage of mice bearing papillomas (A), and as average number of papillomas per mouse (B). = +TPA with vehicle alone A = +TPA with 232 O = +TPA with 236 [54],...

Heliantriol C 3-O-myristate (= Taraxast-20-ene-3P,16P,22a-triol3-0-myristate) (triterpene) Chrysanthemum mortifolium (Asteraceae) TRY (34 pM) [40 pM] [105]... 

Two new taraxastenes, heliantriols C (171) and F (172), have been isolated from the flowers of Helianthus annuus and their structures confirmed by correlation with faradiol (173)/ Further studies of the mass spectral fragmentation of 16-oxotaraxastenes have been published. 

---